Translational infrastructure is coalescing: epithelial cell adhesion molecule (EpCAM)-aptamer nanoarrays with CRISPR/Cas13a quantify tumor-EV miR-21/23a in plasma, and urinary exosomal miR-16 supports rapid, low-cost prostate cancer screening—tools that can guide miRNA therapy selection and monitoring [87,95]. This evidence concerns the gene EPCAM and prostate carcinoma.